0M0F Stock Overview A medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Tandem Diabetes Care, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Tandem Diabetes Care Historical stock prices Current Share Price US$37.50 52 Week High US$54.00 52 Week Low US$21.90 Beta 1.35 1 Month Change 21.36% 3 Month Change -8.60% 1 Year Change 30.81% 3 Year Change -75.31% 5 Year Change n/a Change since IPO -0.82%
Recent News & Updates
Chair Emeritus recently sold US$1.2m worth of stock Nov 24
Third quarter 2024 earnings released: US$0.35 loss per share (vs US$0.51 loss in 3Q 2023) Nov 07
Tandem Diabetes Care, Inc. to Report Q3, 2024 Results on Nov 06, 2024 Oct 03
New major risk - Share price stability Sep 13
Tandem Diabetes Care to Release Updated iOS t:connect Mobile App for t:slim X2 Insulin Pump Users Impacted by March 2024 Nationwide Recall Aug 20
Second quarter 2024 earnings released: US$0.47 loss per share (vs US$0.55 loss in 2Q 2023) Aug 02 See more updates
Chair Emeritus recently sold US$1.2m worth of stock Nov 24
Third quarter 2024 earnings released: US$0.35 loss per share (vs US$0.51 loss in 3Q 2023) Nov 07
Tandem Diabetes Care, Inc. to Report Q3, 2024 Results on Nov 06, 2024 Oct 03
New major risk - Share price stability Sep 13
Tandem Diabetes Care to Release Updated iOS t:connect Mobile App for t:slim X2 Insulin Pump Users Impacted by March 2024 Nationwide Recall Aug 20
Second quarter 2024 earnings released: US$0.47 loss per share (vs US$0.55 loss in 2Q 2023) Aug 02
Tandem Diabetes Care, Inc. to Report Q2, 2024 Results on Aug 01, 2024 Jul 12 Tandem Diabetes Care, Inc.(NasdaqGM:TNDM) dropped from Russell 3000E Value Index
Now 29% undervalued Jul 02
Now 22% undervalued Jun 25
Tandem Diabetes Care, Inc. Appoints Jean-Claude Kyrillos as Executive Vice President and Chief Operating Officer, Effective June 21, 2024 Jun 20
First quarter 2024 earnings released: US$0.65 loss per share (vs US$1.92 loss in 1Q 2023) May 03
Tandem Diabetes Care, Inc. to Report Q1, 2024 Results on May 02, 2024 Apr 10
Now 21% undervalued Mar 14
Now 23% undervalued Feb 28
Full year 2023 earnings released: US$3.43 loss per share (vs US$1.48 loss in FY 2022) Feb 22 Tandem Diabetes Care Launches Tandem Mobi, the World’s Smallest, Durable Automated Insulin Delivery System Feb 13
Tandem Diabetes Care, Inc. to Report Q4, 2023 Results on Feb 21, 2024 Jan 23
Tandem Diabetes Care, Inc. Announces Full U.S. Launch of Tandem Source, a New Diabetes Management Platform for Customers and Healthcare Providers Dec 13
Tandem Diabetes Care, Inc. Launches T:Slim X2 Insulin Pump Software with Dexcom G7 CGM Integration in U.S Dec 06
New major risk - Share price stability Nov 03
Third quarter 2023 earnings released: US$0.51 loss per share (vs US$0.76 loss in 3Q 2022) Nov 02
Tandem Diabetes Care, Inc. Appoints Mark Novara as Executive Vice President and Chief Commercial Officer, Effective November 13, 2023 Nov 02
Tandem Diabetes Care, Inc. to Report Q3, 2023 Results on Nov 01, 2023 Oct 11 Holzer & Holzer, LLC Files Class Action Lawsuit Filed on Behalf of Tandem Diabetes Care, Inc Sep 12
Now 21% undervalued Sep 07
Tandem Diabetes Care, Inc. Announces the Resignation of Brian B. Hansen as Executive Vice President and Chief Commercial Officer, Effective December 31, 2023 Aug 19
Second quarter 2023 earnings released: US$0.55 loss per share (vs US$0.23 loss in 2Q 2022) Aug 04
Now 26% undervalued after recent price drop Aug 01 Tandem Diabetes Care, Inc. Receives U.S. FDA Clearance
Tandem Diabetes Care, Inc. to Report Q2, 2023 Results on Aug 03, 2023 Jul 11
Now 20% undervalued after recent price drop Jul 01
Independent Director recently bought US$295k worth of stock May 25
Executive VP recently bought US$99k worth of stock May 19
First quarter 2023 earnings released: US$1.92 loss per share (vs US$0.23 loss in 1Q 2022) May 06
High number of new directors Apr 24
Full year 2022 earnings released: US$1.48 loss per share (vs US$0.25 profit in FY 2021) Feb 25
Tandem Diabetes Care, Inc. (NasdaqGM:TNDM) completed the acquisition of AMF Medical SA . Jan 24 Tandem Diabetes Care, Inc. to Report Q4, 2022 Results on Feb 22, 2023
Tandem Diabetes Care, Inc. (NasdaqGM:TNDM) entered into a definitive agreement to acquire AMF Medical SA for CHF million. Dec 15
Tandem Diabetes Care, Inc. (NasdaqGM:TNDM) entered into a definitive agreement to acquire AMF Medical SA for CHF million. Dec 14
High number of new directors Nov 16
Tandem Diabetes Care, Inc. Study Demonstrates Improvements of All Clinical Endpoints in Adults with Type 2 Diabetes Using Control-IQ Technology Nov 11
Third quarter 2022 earnings released: US$0.76 loss per share (vs US$0.092 profit in 3Q 2021) Nov 03
Now 24% undervalued after recent price drop Oct 27
Tandem Diabetes Care, Inc. to Report Q3, 2022 Results on Nov 02, 2022 Oct 05
Tandem Diabetes Care Achieves Milestone of 1 Million Insulin Boluses Delivered Using Its t:Connect Mobile App Aug 19
Second quarter 2022 earnings released: US$0.23 loss per share (vs US$0.064 profit in 2Q 2021) Aug 04
Tandem Diabetes Care, Inc. Updates Sales Guidance for the Full Year of 2022 Aug 04
High number of new directors Aug 01
Tandem Diabetes Care, Inc. (NasdaqGM:TNDM) acquired Capillary Biomedical, Inc. Jul 22
Tandem Diabetes Care, Inc. to Report Q2, 2022 Results on Aug 03, 2022 Jul 13
High number of new directors Jul 02
Tandem Diabetes Care Reports the Appointments of Myoung Cha and Joao Malagueira as Independent Members of Its Board of Directors, as of June 15, 2022 Jun 28
Tandem Diabetes Care, Inc. Appoints Myoung Cha and Joao Malagueira as Independent Members of its Board of Directors Jun 17
Executive VP & COO recently sold US$201k worth of stock Jun 12
Executive VP recently bought US$187k worth of stock May 11
First quarter 2022 earnings released: US$0.23 loss per share (vs US$0.081 loss in 1Q 2021) May 06
Tandem Diabetes Care, Inc. Revises Financial Guidance for the Full Year Ending December 31, 2022 May 05
Tandem Diabetes Care, Inc., Annual General Meeting, May 25, 2022 Apr 14
Tandem Diabetes Care, Inc. to Report Q1, 2022 Results on May 04, 2022 Apr 12
Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat Feb 24 Tandem Diabetes Care, Inc. Appoints David B. Berger as Executive Vice President, Chief Operating Officer and Assistant Secretary
Tandem Diabetes Care, Inc. Announces FDA Clearance for the t:slim X2 Insulin Pump to Bolus Using the t:connect Mobile App Feb 17
Third quarter 2021 earnings released: EPS US$0.092 (vs US$0.15 loss in 3Q 2020) Nov 05
Chairman of the Board recently sold US$3.3m worth of stock Sep 04
High number of new and inexperienced directors Aug 31
Chairman of the Board recently sold US$8.9m worth of stock Aug 12
Second quarter 2021 earnings released: EPS US$0.064 (vs US$0.45 loss in 2Q 2020) Aug 05
Tandem Diabetes Care Announces Presentations Demonstrating Positive Real-World Improvements with Control-IQ Technology Across Diverse Populations Jun 30
First quarter 2021 earnings released: US$0.081 loss per share (vs US$0.25 loss in 1Q 2020) May 07
Tandem Diabetes Care, Inc. Revises Earnings Guidance for the Year Ending December 31, 2021 May 06
Chairman of the Board recently sold US$17m worth of stock Mar 19
Full year 2020 earnings released: US$0.56 loss per share (vs US$0.42 loss in FY 2019) Feb 26
Revenue beats expectations Feb 26
Tandem Diabetes Care, Inc. to Report Q4, 2020 Results on Feb 24, 2021 Jan 20
Tandem Diabetes Care, Inc. Announces Executive Changes Dec 16
Chairman of the Board recently sold US$2.4m worth of stock Dec 04
Tandem Diabetes Care Announces Health Canada Approval of the t:slim X2 Insulin Pump with Control-IQ Advanced Hybrid Closed-Loop Technology Nov 25
Chairman of the Board recently sold US$1.9m worth of stock Nov 19
Tandem Diabetes Care, Inc. Updates Sales Guidance for the Fiscal Year Ending December 31, 2020 Nov 06
Tandem Diabetes Care, Inc. to Report Q3, 2020 Results on Nov 05, 2020 Oct 10
First half earnings released Aug 05
Tandem Diabetes Care, Inc. to Report Q2, 2020 Results on Jul 30, 2020 Jul 08 Tandem Diabetes Care, Inc.(NasdaqGM:TNDM) dropped from Russell 2000 Dynamic Index Shareholder Returns 0M0F GB Medical Equipment GB Market 7D 1.4% 0.3% 0.4% 1Y 30.8% -9.1% 3.3%
See full shareholder returns
Return vs Market: 0M0F exceeded the UK Market which returned 2.3% over the past year.
Price Volatility Is 0M0F's price volatile compared to industry and market? 0M0F volatility 0M0F Average Weekly Movement 7.5% Medical Equipment Industry Average Movement 6.5% Market Average Movement 4.7% 10% most volatile stocks in GB Market 10.4% 10% least volatile stocks in GB Market 2.6%
Stable Share Price: 0M0F's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: 0M0F's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of UK stocks.
About the Company Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company’s flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system. It also sells single-use products, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to the user’s body.
Show more Tandem Diabetes Care, Inc. Fundamentals Summary How do Tandem Diabetes Care's earnings and revenue compare to its market cap? 0M0F fundamental statistics Market cap US$2.42b Earnings (TTM ) -US$126.78m Revenue (TTM ) US$854.35m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 0M0F income statement (TTM ) Revenue US$854.35m Cost of Revenue US$428.94m Gross Profit US$425.41m Other Expenses US$552.20m Earnings -US$126.78m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -1.93 Gross Margin 49.79% Net Profit Margin -14.84% Debt/Equity Ratio 146.6%
How did 0M0F perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/31 12:01 End of Day Share Price 2024/12/31 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Tandem Diabetes Care, Inc. is covered by 36 analysts. 21 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Jeffrey Johnson Baird Travis Steed Barclays Matt Miksic Barclays
Show 33 more analysts 
